Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Capital Intensity?

  Amgen Inc ( AMGN ) |
1989 - 2021 (33 years)

Capital Intensity is 
9.82 (1Y -3.24% )

AMGN Stock Price & Capital Intensity

Capital Intensity for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Capital Intensity

chevron_right 2021 9.49 +0.7x
( +1.7% / year avg)
chevron_left 1989 5.44
vertical_align_top Peak 13.88 +2.83x
vertical_align_bottom Bottom 3.63
arrow_drop_up # Up Years 18 18 of 33
years up.
arrow_drop_down # Down Years 15
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1989 , or +1618x faster than it's capital intensity over the same period.
  • If AMGN grows it's stock at the same rate as it's capital intensity (+1.7%/year) , it's stock price will grow +118% and hit $292.06 over the next 10 years.
  • AMGN's stock price has gone up 0 of the 18 years (0%) it's capital intensity were also up.
5-Year Change 🚀
+19.8%$26.5BNet Revenue (Sales)
+49.1%$6.4BCost of Revenue (Sales)
+12.8%$20.1BGross Profit Margin
-5.86%3.04Gross Profit Margin Ratio
+12.4%$4.9BResearch and Development (R&D)
+25.2%$7.1BSelling, General, and Administrative (SG&A)
+24.5%$12.1BTotal Operating Expenses
+32.1%$18.5BCost & Expenses
+12.0%$1.3BInterest Expense/Income, Net
+61.1%$3.5BDepreciation & Amortization (D&A)
+11.9%$11.5BEBITDA
-6.63%1.74EBITDA Margin
-1.23%$8.0BOperating Income
-17.6%1.21Operating Margin
-1.88%$7.5BPretax Income (Earnings)
-18.1%1.13Pretax Income (Earnings) Margin
+131%$1.0BProvision For Income Taxes
-10.3%$6.5BNet Income (Earnings)
-25.1%0.97Net Profit Margin
+15.5%11.04Earnings Per Share (EPS)
+16.5%11.04Earnings Per Share (EPS) Diluted
-22.4%$2.3BShares Outstanding
-23.1%$2.3BShares Outstanding (Diluted)
+51.2%$25.1BCash and Cash Equivalents
-83.9%$17.5BShort Term Investments
-66.1%$42.6BCash And Short-Term Investments
+59.9%$15.6BInventory
+21.9%$8.3BOther Current Assets
-45.1%$84.6BTotal Current Assets
+42.5%$66.3BIntangible Assets
+18.3%$125.1BGoodwill and Intangible Assets
-12.1%$251.8BTotal Assets
+47.3%$5.7BAccounts Payables
-96.0%$364.0MShort-term Debt
+34.5%$46.6BTotal Current Liabilities
+12.2%$131.6BLong-term Debt
-38.3%$8.1BOther Non-Current Liabilities
+20.3%$167.5BTotal Non-Current Liabilities
+23.1%$214.2BTotal Liabilities
+3.76%$127.2BCommon Stock
+926%-$85.6BRetained Earnings
+105%-$3.9BAccumulated Other Comprehensive Income Loss
-66.5%$37.6BTotal Shareholders Equity
-12.1%$251.8BTotal Liabilities & Stockholders Equity
+4.53%$131.9BTotal Debt
-2.52%$106.9BNet Debt
-114.6%$208.0MDeferred Income Tax
+312%$1.3BStock-Based Compensation (SBC)
+76.0%-$12.9BChange in Working Capital
+235%-$1.6BAccounts Receivables
-68.2%$38.0BOther Working Capital
+161%-$1.9BOther Non-Cash Items
+4.51%$8.6BNet Cash Provided by Operating Activities
-15.6%-$692.0MInvestments in PP&E
-49.1%-$12.6BPurchase of Investments
-69.0%$8.2BSales/Maturities of Investments
-48.8%-$164.0MOther Investing Activities
+493%-$5.5BNet Cash used for Investing Activities
+1,060%-$5.8BDebt Repayment
+558%-$4.8BCommon Stock Repurchased
+56.4%-$3.7BDividends Paid
-87.0%-$12.0MOther Financing Activities
+294%-$14.4BNet Cash Used Provided by Financing Activities
-407.3%-$11.3BNet Change in Cash
+51.2%$25.1BCash at End of Period
+181%$36.3BCash at Beginning of Period
+4.51%$8.6BOperating Cash Flow
-15.6%-$692.0MCapital Expenditure (capex)
+6.74%$7.9BFree Cash Flow
  • AMGN Historical Capital Intensity Table

    Year Capital Intensity YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 9.49 -5.5% - -
    4/1/2020 10.05 -5.8% - -
    4/1/2019 10.67 -13.2% - -
    4/1/2018 12.29 -10.4% - -
    4/1/2017 13.72 3.1% - -
    4/1/2016 13.31 1.5% - -
    4/1/2015 13.12 -5.5% - -
    4/1/2014 13.88 16.3% - -
    4/1/2013 11.93 -2.5% - -
    4/1/2012 12.24 5.8% - -
    4/1/2011 11.58 5.8% - -
    4/1/2010 10.94 3.7% - -
    4/1/2009 10.55 10.0% - -
    4/1/2008 9.59 7.3% - -
    4/1/2007 8.94 -1.8% - -
    4/1/2006 9.1 -3.7% - -
    4/1/2005 9.45 -10.4% - -
    4/1/2004 10.55 -18.9% - -
    4/1/2003 13.01 35.6% - -
    4/1/2002 9.59 57.5% - -
    4/1/2001 6.09 12.9% - -
    4/1/2000 5.39 8.5% - -
    4/1/1999 4.97 -3.8% - -
    4/1/1998 5.17 4.2% - -
    4/1/1997 4.96 6.6% - -
    4/1/1996 4.65 -0.3% - -
    4/1/1995 4.67 -2.7% - -
    4/1/1994 4.8 12.3% - -
    4/1/1993 4.27 2.3% - -
    4/1/1992 4.18 15.2% - -
    4/1/1991 3.63 -20.8% - -
    4/1/1990 4.58 -15.9% - -
    4/1/1989 5.44 - - -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
  • Capital intensity = Average Total assets /Net Sales


    For more detailed definitions, please see Investopedia.
    Year Capital Intensity YoY % Change Stock Price YoY % Change (Stock Price) net revenue total assets
    4/1/2021 9.49 -5.5% 26536.00 251792.00
    4/1/2020 10.05 -5.8% 24987.00 251024.00
    4/1/2019 10.67 -13.2% 23395.00 249321.00
    4/1/2018 12.29 -10.4% 23319.00 286135.00
    4/1/2017 13.72 3.1% 23012.00 315406.00
    4/1/2016 13.31 1.5% 22562.00 300313.00
    4/1/2015 13.12 -5.5% 21457.00 281039.00
    4/1/2014 13.88 16.3% 19743.00 273438.00
    4/1/2013 11.93 -2.5% 18086.00 215621.00
    4/1/2012 12.24 5.8% 16817.00 205795.00
    4/1/2011 11.58 5.8% 15450.00 178901.00
    4/1/2010 10.94 3.7% 15021.00 164329.00
    4/1/2009 10.55 10.0% 14584.00 153603.00
    4/1/2008 9.59 7.3% 14997.00 143826.00
    4/1/2007 8.94 -1.8% 14861.00 132781.00
    4/1/2006 9.10 -3.7% 13704.00 124486.00
    4/1/2005 9.45 -10.4% 12068.00 113811.00
    4/1/2004 10.55 -18.9% 9987.20 105026.90
    4/1/2003 13.01 35.6% 7775.80 100436.10
    4/1/2002 9.59 57.5% 4801.20 48386.70
    4/1/2001 6.09 12.9% 3797.20 23121.90
    4/1/2000 5.39 8.5% 3390.13 18274.27
    4/1/1999 4.97 -3.8% 3148.64 15595.60
    4/1/1998 5.17 4.2% 2502.70 12922.50
    4/1/1997 4.96 6.6% 2335.80 11584.40
    4/1/1996 4.65 -0.3% 2120.30 9845.10
    4/1/1995 4.67 -2.7% 1833.80 8554.80
    4/1/1994 4.80 12.3% 1556.60 7434.20
    4/1/1993 4.27 2.3% 1398.40 5974.00
    4/1/1992 4.18 15.2% 1199.60 5010.80
    4/1/1991 3.63 -20.8% 711.60 2580.00
    4/1/1990 4.58 -15.9% 340.00 1545.40
    4/1/1989 5.44 192.67 971.07